New York, Jan 11, 2026, 09:36 EST — Market closed.
- Amazon Pharmacy now offers Novo Nordisk’s Wegovy weight-loss pill, available through both insurance and cash-pay choices
- Shares of Amazon.com ended the day 0.44% higher, closing at $247.38
- Investors enter the week with eyes on Tuesday’s U.S. inflation figures and the first batch of earnings reports
Amazon.com’s online pharmacy has started selling Novo Nordisk’s newly approved Wegovy weight-loss pill, expanding the retailer’s health services just before the next U.S. trading session.
On Friday, Amazon shares ended the day 0.44% higher, closing at $247.38.
Amazon’s new launch marks its entry into the fast-growing GLP-1 drug market—medicines that promote weight loss by mimicking a hormone that regulates appetite and blood sugar. The move comes as investors hunt for growth avenues outside the company’s mainstays, e-commerce and Amazon Web Services.
Macro forces could take center stage in the near term. Tuesday brings December’s Consumer Price Index (CPI), a critical U.S. inflation measure, alongside the kickoff of quarterly earnings from major U.S. banks. These developments have the potential to shift expectations around Federal Reserve rate cuts and shake up mega-cap tech stocks. “As we’re starting January, the market may be underappreciating some of the events on the horizon that could likely produce higher volatility,” said Michael Arone, chief investment strategist at State Street Investment Management. Reuters
Amazon Pharmacy announced eligible customers with commercial insurance could pay as little as $25 for a one-month supply, while a cash-pay option starts at $149 monthly. Tanvi Patel, the company’s vice president and general manager, said the aim is to provide “more choice, greater transparency, and fewer barriers to care.” Amazon plans to deliver the pill nationwide, add it to pharmacy kiosks in the coming weeks, and collaborate with WeightWatchers, Wheel, and 9amHealth. One Medical will provide related clinical support. Business Wire
The FDA gave the green light to Novo’s once-daily Wegovy pill in December. It packs the same active ingredient found in the injectable versions of Wegovy and Ozempic. Novo plans to sell 1.5 mg and 4 mg doses at $149 a month for U.S. patients paying out of pocket. The pill will be stocked at pharmacies like CVS and Costco, and offered through telehealth platforms including Ro, LifeMD, WeightWatchers, and GoodRx.
Amazon shares ended Friday at $247.38, marking a roughly 0.4% gain from the previous day, market data showed.
Amazon’s push into pharmacies puts it in closer contention with major drugstore chains. It also links the company more firmly to a drug sector that’s transforming pharmacy demand and employer benefits.
Investors continue to view healthcare as a “prove it” sector for Amazon. Any boost in revenue from obesity drugs will likely be measured against the costs of securing prescriptions, managing deliveries, and maintaining seamless customer service.
The risk here is that adoption falls short if insurance coverage remains patchy and cash-pay interest wanes once early adopters move on. Sudden changes in supply, pricing, or reimbursement can shake the market—and those shocks can dent sentiment, even when short-term revenue stays limited.
The next major event is Tuesday, Jan. 13, when U.S. CPI data drops. If the numbers surprise on the upside, yields might climb, putting pressure on rate-sensitive tech names like Amazon — no matter what’s happening in the pharmacy sector.
Related articles: NASDAQ:AMZN
